the LAR must act in the best interest of the participant and provide consent that is fully informed and voluntary. Ethical guidelines require clear documentation of LAR status and rationale for their involvement.

Duties and Responsibilities of a LAR:

1. Receive complete information about the trial, including risks, benefits, alternatives, and the right to withdraw
2. Understand and evaluate the implications of participation on behalf of the subject
3. Provide signed informed consent and remain available for re-consent if the protocol changes
4. Ensure the subject’s rights, safety, and well-being are upheld throughout the trial

The consent process with LARs must be thoroughly documented using pharma SOP templates to comply with EC and audit expectations.

Process of Engaging a LAR in the Consent Workflow:

1. Verify Eligibility

• Confirm that the subject cannot provide informed consent
• Verify legal documents establishing LAR authority (court order, guardianship papers, etc.)

2. Provide Trial Information

• Use plain language explanations
• Offer printed materials in the regional language
• Ensure sufficient time for questions

3. Document Consent

• LAR signs the informed consent form (ICF)
• Include date, version number, and impartial witness if needed
• Capture audio-visual documentation if required by regulation (e.g., in India)

Ongoing Responsibilities of LARs During the Trial:

• Monitor the subject’s willingness or behavioral signs of dissent
• Authorize protocol amendments requiring re-consent
• Ensure availability for emergency decision-making (e.g., SAE responses)

Participant protection and compliance also involve product quality data supported by stability testing protocols relevant to the subject’s condition or administration route.

Ethics Committee Review of LAR Involvement:

• Evaluate if LAR involvement is scientifically and ethically justified
• Review consent documents for LAR-specific sections
• Ensure impartiality and lack of conflict of interest

Best Practices for Working with LARs:

1. Use a checklist to confirm LAR eligibility and documentation
2. Maintain a separate file in the Trial Master File for LAR forms and logs
3. Conduct periodic re-confirmation of the LAR’s authority and engagement
4. Train site staff on LAR engagement and documentation SOPs
5. Be sensitive to cultural and legal differences in LAR roles across jurisdictions

These steps should align with GMP documentation practices for ethical compliance and traceability.

Assent in Parallel with LAR Consent:

In some cases (e.g., cognitively impaired adults or children), the subject may still be capable of providing assent. This should be:

• Documented in a simplified Assent Form
• Accompanied by the LAR’s formal consent
• Respected even if the LAR provides approval (i.e., a dissenting subject should not be enrolled)

Common Pitfalls and How to Avoid Them:

• Not validating LAR status with proper documentation
• Overlooking the need for re-consent upon protocol changes
• Failure to assess subject’s own willingness or distress
• Improper filing or missing AV recordings (where required)

Legal Considerations Across Jurisdictions:

• Laws differ regarding who can act as a LAR (e.g., India’s Mental Healthcare Act, 2017)
• In some countries, next-of-kin may suffice; in others, a court order is mandatory
• Sponsors and investigators must consult legal experts or compliance teams when expanding to new regions

Conclusion:

Legally Authorized Representatives serve a crucial function in protecting the rights of vulnerable clinical trial participants. Their engagement must be handled with clarity, documentation, and respect for both ethical and regulatory frameworks. A robust SOP-backed system for LAR consent helps ensure transparency, compliance, and trust—cornerstones of ethical clinical research.